Home » Stocks » Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. (AUPH)

Stock Price: $14.17 USD -0.01 (-0.07%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $14.23 +0.06 (0.42%) Aug 13, 7:17 PM

Stock Price Chart

Key Info

Market Cap 1.60B
Revenue (ttm) 318,000
Net Income (ttm) -141.58M
Shares Out 126.25M
EPS (ttm) -1.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $14.17
Previous Close $14.18
Change ($) -0.01
Change (%) -0.07%
Day's Open 14.23
Day's Range 13.98 - 14.34
Day's Volume 983,578
52-Week Range 3.52 - 21.93

More Stats

Market Cap 1.60B
Enterprise Value 1.34B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 126.25M
Float 82.05M
EPS (basic) -1.43
EPS (diluted) -1.37
FCF / Share -0.74
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.83M
Short Ratio 1.88
Short % of Float n/a
Beta 1.03
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 5,022.11
PB Ratio 6.80
Revenue 318,000
Operating Income -107.46M
Net Income -141.58M
Free Cash Flow -82.66M
Net Cash 258.15M
Net Cash / Share 2.29
Gross Margin -16,524.53%
Operating Margin -33,791.51%
Profit Margin -44,521.10%
FCF Margin -25,994.03%
ROA -27.23%
ROE -77.60%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 10
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(77.13% upside)
Current: $14.17
Target: 25.10
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-31.32%10.77%141.62%-26.38%-15.47%-71.31%-84.18%-
Gross Profit0.320.460.420.
Operating Income-85.24-56.33-46.87-25.03-23.71-16.65-6.57-9.69
Net Income-124-64.12-70.79-23.30-18.61-19.42-2.66-9.69
Shares Outstanding85.5084.0552.8132.2931.8231.3731.37-
Earnings Per Share-1.33-0.76-0.92-0.66-0.58-0.67-0.42-2.73
Operating Cash Flow-63.46-51.61-41.17-18.71-17.77-16.91-4.62-6.51
Capital Expenditures-0.10-0.08-0.03-0.01-0.05-0.09-0.04-
Free Cash Flow-63.56-51.69-41.19-18.72-17.82-16.99-4.66-6.51
Cash & Equivalents30612617339.6515.7532.701.820.19
Total Debt------1.321.71
Net Cash / Debt30612617339.6515.7532.700.50-1.52
Book Value27411316635.9519.9633.8713.31-2.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aurinia Pharmaceuticals Inc.
Country Canada
Employees 62
CEO Peter S. Greenleaf

Stock Information

Ticker Symbol AUPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AUPH
IPO Date January 26, 1999


Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.